Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate if acute ingestion of L-arginine will enhance anaerobic exercise performance in young, healthy, and recreationally active adults.
After being enrolled in the study you will be measured on a number of parameters including: body circumferences, body composition via bioelectrical impedance analysis (BIA), height, weight, resting blood pressure, and resting heart rate. All participants will be asked to complete the same protocol for this study. The study design is a randomized, double-blind, placebo controlled, cross-over type of study. What this means is that each participant in the study will complete two exercise sessions after ingesting either a placebo (dextrose - a sugar molecule) or the active ingredient \[insert supplement\] plus dextrose. Neither you nor the research assistant testing you on the exercise sessions will know which ingredient you are ingesting before each exercise trial (i.e., the double-blind portion of the study). We will also randomize the order of which supplement plus placebo or placebo alone you will ingest so neither you nor the research assistant testing will know this either. The cross-over part of the study is that you will complete 2 testing sessions to assess some physical performance variables (grip strength, jump height and power, and anaerobic energy system power output) with one-week of a wash-out period between them. This will allow us to compare the placebo session to the active nutritional supplement plus placebo condition to evaluate if the supplements improve exercise performance acutely. You will also be asked to fill in a 24-hour food and fluid log for the period before your initial exercise test. Then you will be asked to repeat this food and fluid intake when completing the second session. No caffeine, alcohol, or vigorous exercise will be allowed for the 24-hours prior to each trial.
Age
18 - 39 years
Sex
ALL
Healthy Volunteers
Yes
Applied Research Centre; Active Living Centre
Winnipeg, Manitoba, Canada
Start Date
June 14, 2024
Primary Completion Date
September 1, 2024
Completion Date
December 31, 2024
Last Updated
June 26, 2024
20
ESTIMATED participants
L-arginine
DIETARY_SUPPLEMENT
Placebo
DIETARY_SUPPLEMENT
Lead Sponsor
University of Manitoba
NCT06188767
NCT06317116
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06810271